



ABN 53 075 582 740

ASX ANNOUNCEMENT

9 November 2011

Bionomics Limited (ASX:BNO) hereby gives notice to the Australian Securities Exchange ("ASX") that shareholders of the company passed all resolutions considered before the Annual General Meeting today.

The Notice of Annual General Meeting and accompanying documents were lodged with ASX on 7 October 2011.

This notice is given in accordance with ASX Listing rule 3.13.2 and section 251AA of the Corporations Act 2001.

Resolution Number	Resolutions	Result	Proxy Votes			
			For	Against	Open	Abstain
1	Adoption of Remuneration Report	Passed on a show of hands	116,847,345	3,647,387	174,481	61,881
2	Re-election of Non-Executive Director - Mr Christopher Fullerton	Passed on a show of hands	119,765,374	193,992	857,062	70,400
3	Approval of Proposed Issue of Share Options to Dr Deborah Rathjen - Y/E 30 June 2011	Passed on a show of hands	114,514,946	6,045,972	112,700	47,476
4	Approval of Proposed Issue of Share Options to Dr Deborah Rathjen - Long term incentive	Passed on a show of hands	114,375,582	6,209,321	112,700	33,491
5	Approval of Proposed Issue of Share Options to Dr Deborah Rathjen - Commercialisation incentive	Passed on a show of hands	114,107,871	6,470,782	112,700	39,741
5	Approval of Bionomics Limited Employee Share Option Plan	Passed on a show of hands	114,625,743	5,931,077	112,700	21,501

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 / 0418 160 425
drathjen@bionomics.com.au

Ms Melanie Young
CFO & Company Secretary
+618 835 46107 / 0418 848 703
myoung@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. BNC105, which is undergoing clinical development for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. A clinical program is also underway for the treatment of anxiety disorders based on BNC210 which exhibits strong anxiolytic activity without side effects in preclinical models. Both compounds offer blockbuster potential if successfully developed.

Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels). MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system.

For more information about Bionomics, visit www.bionomics.com.au